Sera Prognostics (NASDAQ:SERA – Get Free Report) and Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.
Institutional and Insider Ownership
54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Sera Prognostics and Cardio Diagnostics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sera Prognostics | $80,000.00 | 991.18 | -$31.93 million | ($0.67) | -3.00 |
| Cardio Diagnostics | $10,000.00 | 559.44 | -$6.50 million | ($2.53) | -0.75 |
Cardio Diagnostics has lower revenue, but higher earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Sera Prognostics has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for Sera Prognostics and Cardio Diagnostics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
Sera Prognostics presently has a consensus target price of $5.50, suggesting a potential upside of 173.63%. Given Sera Prognostics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Sera Prognostics is more favorable than Cardio Diagnostics.
Profitability
This table compares Sera Prognostics and Cardio Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sera Prognostics | -34,866.67% | -52.54% | -36.97% |
| Cardio Diagnostics | -40,543.75% | -89.41% | -82.81% |
Summary
Sera Prognostics beats Cardio Diagnostics on 12 of the 15 factors compared between the two stocks.
About Sera Prognostics
Sera Prognostics, Inc. is a women’s health company focused on identifying pregnancy risks through blood-based testing and biomarker research. The company develops diagnostic products intended to help healthcare providers assess pregnancy outcomes and support individualized care. Its lead product, the PreTRM test, analyzes proteins in a pregnant patient’s blood to estimate the risk of spontaneous preterm birth. The company has developed the test for use by healthcare providers in the United States and continues to study its potential role in pregnancy care.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. is a biotechnology company developing artificial intelligence-powered precision medicine products for the prevention and management of cardiovascular disease. Its approach combines genetic, epigenetic and clinical information to help identify individuals at elevated risk and support more personalized care. The company’s product portfolio includes Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease and provide information that may guide prevention strategies.
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.
